

5  
46. (E)-(1R,1'R)-2,2'-[4-Octenedioylbis(oxytri-  
methylene)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-  
(3,4,5-trimethoxybenzyl)isoquinolinium] cation in association  
with a pharmaceutically acceptable anion.

4  
47. (E)-(1R,1'R)-2,2'-[4-Octenedioylbis(oxytri-  
methylene)]bis[1,2,4,3-tetrahydro-6,7-dimethoxy-2-methyl-1-  
(3,4,5-trimethoxybenzyl)isoquinolinium] dichloride

2  
48. (E)-(1R,1'R,2R,2'R)-2,2'-[4-Octenedioylbis(oxytri-  
methylene)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-  
(3,4,5-trimethoxybenzyl)isoquinolinium] cation in association  
with a pharmaceutically acceptable anion.

8  
49. (E)-(1R,1'R,2R,2'R)-2,2'-[4-Octenedioylbis(oxytri-  
methylene)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-  
(3,4,5-trimethoxybenzyl)isoquinolinium] dichloride

9  
50. (E)-(1R,1'R,2R,2'S)-2,2'-[4-Octenedioylbis(oxytri-  
methylene)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-  
(3,4,5-trimethoxybenzyl)isoquinolinium] cation in association  
with a pharmaceutically acceptable anion.

10  
51. (E)-(1R,1'R,2R,2'S)-2,2'-[4-Octenedioylbis(oxytri-  
methylene)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-  
1-(3,4,5-trimethoxybenzyl)isoquinolinium] dichloride

11  
52. (E)-(1R,1'R,2S,2'S)-2,2'-[4-Octenedioylbis(oxytri-  
methylene)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-  
(3,4,5-trimethoxybenzyl)isoquinolinium] cation in association

Serial No. 756,025

with a pharmaceutically acceptable anion.

<sup>12</sup>  
53. (E)-(1R,1'R,2S,2'S)-2,2'-[4-Octenedioylbis(oxytri-  
methylene)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-  
(3,4,5-trimethoxybenzyl)isoquinolinium] dichloride

<sup>13</sup>  
54. A method for producing muscle relaxation in a mammal  
which comprises parenterally administering to a mammal an  
effective muscle relaxant amount of the compound of claim <sup>1 3</sup>42, <sup>44</sup>44  
or <sup>46</sup>46.

<sup>14</sup>  
55. A sterile pharmaceutical composition comprising one or  
more of the compounds of claims <sup>1 2 3 4 5 6 7 8</sup>42, 43, 44, 45, 46, 47, 48, 49,  
<sup>9 10 11 12</sup>50, 51, 52 or 53 in an effective muscle relaxant amount and a  
pharmaceutically acceptable solvent therefor.

<sup>15</sup>  
56. A method for producing muscle relaxation in a mammal  
which comprises parenterally administering to a mammal an  
effective muscle relaxant amount of one or more of the compounds  
of claims <sup>9 10 11 12</sup>50, 51, 52 or 53.

#### REMARKS

Applicants have cancelled claims 19 to 41 and inserted re  
written claims 42 to 56 to reduce the claims to 15 in number and  
at the same time adequately cover the invention.

Claims 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 and 53  
track Examples 1, 2, 3 and 4 and claim compounds disclosed as C  
(Example 1), D (Example 2), G (Example 3), H, I, J (Example 4).

For the claims 42, 44, 46, 48, 50 and 52 the anion is